Work

The Microbiota–Metabolism Axis: Mechanistic Insights and Translational Targets Across Diabetes and Gastrointestinal Disorders

Year: 2026
Type: review
Abstract: The gut microbiota (GM) modulates host energy balance, glucose-lipid metabolism, and enteroendocrine signaling through metabolite-receptor axes that include short-chain fatty acids (SCFAs) acting on FFAR2/FFAR3 (GPR43/GPR41), microbially transformed bile acids signaling via FXR/TGR5, and amino-acid/choline-derived compounds such as imidazole propionate (ImP) and trimethylamine N-oxide (TMAO). These pathways regulate incretin biology (GLP-1/PYY), insulin sensitivity, hepatic glucose output, adipose lipolysis, and appetite, thereby shaping risk and progression of Type 2 diabetes mellitus (T2DM), obesity, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and related conditions. Here, we synthesize mechanistic and translational evidence, highlight bidirectional drug-microbiome interactions (GLP-1 receptor agonists), and review interventions spanning diet, pre/probiotics, fecal microbiota transplantation (FMT), and pharmacologic targeting of bile-acid and SCFA pathways. Together, these findings support precision strategies that profile GM-metabolite signatures (e.g., SCFAs, secondary bile acids, and ImP TMAO) to guide prevention and therapy in metabolic and gastrointestinal disease.
Language: English
Open Access status: gold
Estimated APC paid: $2,830
OpenAlex ID: W7225696553
FWCI:
Cites: 65
Cited by:
Related to: 10